1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. ROYALTY PHARMA PLC - ORDINARY SHARES - CLASS A
Royalty Pharma plc - Ordinary Shares - Class A
XNAS: RPRX
Mid-range Performer
Download real time
60.961.34(2.25%)
69.71% Gain from 52W Low
5.8M
XNAS Volume

XNAS 16 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Dividend
Royalty Pharma PLC (Class A) has an upcoming dividend of $0.235 per share due on 13 Nov 2026See details

Royalty Pharma PLC (Class A) quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Royalty Pharma PLC (Class A) share price target, revenues, EPS, net income and more

Royalty Pharma PLC (Class A) quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • POSITIVE

    Quarterly Revenue Royalty Pharma PLC (Class A) Jun-2026 Quarterly Revenue is $674 Million which is growth of 16.5% YoY.

  • NEGATIVE

    Quarterly Net Profit Royalty Pharma PLC (Class A) Jun-2026 Quarterly Net Profit is $18 Million which is growth of -40.7% YoY.

Royalty Pharma plc - Ordinary Shares - Class A, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
674.1630.6622609.3578.7568.3593.6564.7537.3568596.1536.3538.2
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
541-1.9233.6182.1368.934.1232.1-170.4267.6641.8-16.8384.9289.4
Operating Profit
133.1632.5388.4427.2209.8534.2361.5735.1269.6-73.8612.9151.4248.8
⌄
-88.5-87.5-87.1-72.7-60.3-54-56.7-49-35.6-36.8-40.8-22.6-21.3
Profit Before Tax
81.5468.3355.9444.290.6433.4334.4806.4194.4-4.3717.6122.1351.3
Tax
⌄
17.9294.7214.2288.230.2238.4208.25441024.8887.172.1227.6
Diluted NI Avail to Com Stockholders Ann.
22.3375.2278.1372.439.9238.4275.3719.4134.94.8661.796.2305.7
Basic EPS
00.70.50.70.10.60.51.20.201.10.20.5
Diluted EPS After ExtraOrdinary
-00.80.30.50.20.60.410.3-0.20.80.20.3
Number Of Shares End
445.1436.8428.4431.9423.5435.5445.5447.6451448.6445.9448.4450.4
Net Income Continuing Discontinued Operations
17.9294.7214.2288.230.2238.4208.25441024.8494.372.1227.6
Normalized Income
-477.191.6-169.6-136.6-305.8-55.4-227.1162.2-316.9-669.4-90.9-263.7-305.2
Interest Income
5.16.27.16.98.311.3917.513.47.46.523.425.7
Interest
93.693.794.279.668.765.365.866.54944.247.34647
Net Interest Income
-88.5-87.5-87.1-72.7-60.3-54-56.7-49-35.6-36.8-40.8-22.6-21.3
EBIT
170555.8443516.9151487.4391.1855.423032.5758.3144.7372.6
EBITDA
171.3556.9444.2518.2151487.4391.1855.423032.5758.3144.7372.6
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
1.31.21.21.3------
Profit From Continuing Operations
81.5468.3355.9444.290.6433.4334.4806.4194.4-4.3717.6122.1351.3
Normalized EBITDA
142.1659.4392.5449.7219.3548.9400761.3290.7-84.2601.4168274.8
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Royalty Pharma PLC (Class A) competitor comparison and performance snapshot within industry

Royalty Pharma PLC (Class A) annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Annual Revenue Royalty Pharma PLC (Class A) Dec-2025 Annual Revenue is $2,378 Million which is growth of 5.1% YoY.

  • NEGATIVE

    Annual Net Profit Royalty Pharma PLC (Class A) Dec-2025 Annual Net Profit is $771 Million which is growth of -10.2% YoY.

Royalty Pharma plc - Ordinary Shares - Class A, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17
⌄
2.1%
2.3%
 2,378.22,263.62,354.62,237.22,289.52,122.41,814.31,794.91,597.9
Cost Of Rev. Ann.
-
-
 ---------
Gross Profit Ann.
-
-
 ---------
Operating Exp. Ann.
-14.6%
9.2%
954.9818.7971.1862.41,314.3858.8527-808.9430.5658.2
Operating Profit Ann.
19.1%
-0.5%
1,581.11,559.51,292.41,492.2922.91,430.71,595.42,623.21,364.5939.7
⌄
-
-
-335.7-274.1-178.2-114.9-109.6-112.6-128.7-246.2-255.5-240.6
Other Exp. Ann.
-
-30.3%
 38.8216.5322.8-583.2-76.9235.284.5408.9644.1
PBT Ann.
79.2%
-4.9%
1,349.91,324.21,330.81,700.1230.11,241.21,7022,461.41,517.91,343.2
Tax Ann.
-
-
 
⌄
162.1%
9.3%
8157718591,527.642.8619.7495.21,187.31,377.71,210
Diluted NI Avail to Com Stockholders Ann.
186.4%
15.2%
1,0481,005.51,135.91,527.642.8619.7495.21,187.31,377.71,210
EPS Ann.
162.1%
-
 1.81.9-0.11.5-3.43.93.4
Diluted EPS Ann.
162.1%
-
 1.81.9-0.11.5-3.43.93.4
Number Of Shares End
-1.1%
1.5%
 428.4445.5445.9442.2431.4398.5354.2--
Total Exp. Ann.
-14.6%
9.2%
 818.7971.1862.41,314.3858.8527-808.9430.5658.2
Net Income Continuing Discontinued Operations Ann.
162.1%
-4.6%
8157718591,134.842.8619.79752,348.51,377.71,210
Normalized Income Ann.
-
-
-691.7-671.1-1,004.7-811-1,333-769.31,3322,344.8667449.1
Interest Income Ann.
-24.6%
3.4%
25.333.647.372.378.353.528.422.324.46.8
Interest Ann.
17.8%
14.4%
361.1307.7225.5187.2188166.1157.1268.6280247.3
EBITDA Ann.
66.8%
-2.9%
1,690.51,602.11,5091,815345.41,376.81,853.72,731.61,806.61,617
Reconciled Cost Of Rev. Ann.
-
-
 ---------
Reconciled Depr. Ann.
-11.9%
-29.9%
4.93.95.72323.123.933.333.3
Profit From Continuing Operations Ann.
79.2%
-4.9%
1,349.91,324.21,330.81,700.1230.11,241.21,7022,461.41,517.91,343.2
Normalized EBITDA Ann.
17.9%
-0.6%
1,643.81,611.71,367.91,571.6983.21,482.11,658.52,637.31,413.61,141.9
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
5.1%
2Y CAGR
0.5%
3Y CAGR
2.1%
5Y CAGR
2.3%
7Y CAGR
4.1%
Total Revenue Annual growth is higher than historical averages.
Net Profit Ann.
1Y CHG
-10.2%
2Y CAGR
-17.6%
3Y CAGR
162.1%
5Y CAGR
-4.6%
7Y CAGR
-8%
Net Profit Annual is falling faster than historical averages.
Operating Exp. Ann.
1Y CHG
-15.7%
2Y CAGR
-2.6%
3Y CAGR
-14.6%
5Y CAGR
9.2%
7Y CAGR
9.6%
Operating Expenses Annual Cr is falling faster than historical averages.

Royalty Pharma PLC (Class A) balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Total Shareholders Fund Royalty Pharma PLC (Class A) Dec-2025 Total Shareholders Fund is $6,477 Million which is growth of -6.8% YoY.

  • POSITIVE

    Total Assets Royalty Pharma PLC (Class A) Dec-2025 Total Assets is $19,621 Million which is growth of 7.7% YoY.

Royalty Pharma plc - Ordinary Shares - Class A, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17
⌄
5.3%
4.1%
19,620.818,222.716,381.916,813.517,515.916,020.312,449.911,370.2-
⌄
10.8%
10.1%
9,905.87,880.46,297.67,288.17,267.36,124.56,308.56,818.1-
⌄
4.8%
6.1%
6,476.96,946.66,526.55,628.25,776.64,818.86,105.64,488.2-
Total Capitalization Ann.
8.6%
7.2%
15,047.813,561.212,661.811,74712,872.710,635.412,061.710,726.1-
Tangible Assets Ann.
-0.5%
3%
5,552.36,946.66,526.55,628.25,770.94,790.16,053.84,412.6-
Working Capital Ann.
-13.7%
-17.9%
891.9548.51,112.81,388.12,7072,389498.72,028.4
Invested Capital Ann.
6.6%
7.7%
15,427.814,55912,661.812,744.512,872.710,635.412,343.711,007.6-
Tangible Book Value Ann.
-0.5%
3%
5,552.36,946.66,526.55,628.25,770.94,790.16,053.84,412.6-
Borrowings Ann.
7.9%
9%
8,950.97,612.46,135.37,116.37,096.15,816.66,238.16,519.3-
Net Debt Ann.
15.5%
11.6%
8,332.26,683.45,658.35,405.65,5554,807.95,954.44,595.1-
Share Issued Ann.
-1.1%
2%
428.7446446.7443.2433388.1350.6350.6-
Number Of Shares End
-1.1%
1.5%
428.4445.5445.9442.2431.4398.5354.2--
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
7.7%
2Y CAGR
9.4%
3Y CAGR
5.3%
5Y CAGR
4.1%
7Y CAGR
8.1%
Total Assets Annual growth is stable compared to historical averages.
Total Current Liabilities Ann.
1Y CHG
-49.3%
2Y CAGR
98.5%
3Y CAGR
-18.3%
5Y CAGR
15.6%
7Y CAGR
1.3%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
-6.8%
2Y CAGR
-0.4%
3Y CAGR
4.8%
5Y CAGR
6.1%
7Y CAGR
5.4%
Total ShareHolders Funds Annual is falling faster than historical averages.

Royalty Pharma PLC (Class A) ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Book Value Per Share Royalty Pharma PLC (Class A) Book Value Per Share is $15 which is growth of -5.7% YoY.

  • NEUTRAL

    ROE Royalty Pharma PLC (Class A) ROE is 0% which is growth of 0% YoY.

Royalty Pharma plc - Ordinary Shares - Class A, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17
RoA Ann. %
-
-
-4.96%9.20%0.25%3.70%3.48%9.97%12.12%-
ROE Ann. %
-
-
-12.75%25.14%0.75%11.70%9.07%22.41%30.70%-
ROIC %
-
-
-1.87.4-3.50.3-2.82.6--
OPM Ann. %
16.7%
-2.7%
65.58%57.10%63.37%41.25%62.49%75.17%144.59%76.02%58.81%
Inventory Turnover Ratio Ann.
-
-
---------
Asset Turnover Ann. %
-
-
-0.10.10.10.10.20.20.2-
Working Capital Turnover Ann.
19.1%
24.6%
2.74.12.11.60.90.93.60.9-
Quick Ratio Ann.
-
-
-1.47.92.116.88.72.54.5-
Current Ratio Ann.
-
-
-1.47.92.216.88.82.54.5-
Interest Coverage Ratio Ann.
-
-
-6.910.12.28.511.810.26.46.4
LT Debt To Equity Ann.
-
-
-10.91.11.21.211.4-
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Royalty Pharma PLC (Class A) cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Royalty Pharma PLC (Class A) Dec-2025 Cash From Operating Activity is $2,490 Million which is growth of -10.1% YoY.

  • NEGATIVE

    Net Cash Flow Royalty Pharma PLC (Class A) Dec-2025 Net Cash Flow is $-310 Million which is growth of -168.7% YoY.

Royalty Pharma plc - Ordinary Shares - Class A, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17
⌄
5.1%
4.1%
2,489.82,7692,987.82,1442,017.52,034.61,667.21,618.31,418.3
⌄
-
-
-1,614.2-2,678.1-2,072.8-1,029.4-1,870.3-2,759.3-2,116.1303.4-1,587.7
⌄
-
-
-1,186361.1-2,148.8-944.9385.11,487.2-1,191.6-1,379.1-123.3
Cash Plus Cash Eqv. End Of Year Ann.
-28.8%
-9.3%
618.79294771,710.81,541.11,008.7283.71,924.21,381.6
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-310.3452-1,233.7169.7532.4762.5-1,640.5542.6-292.7
Cash Plus Cash Eqv. Begin Of Year Ann.
-15.5%
30.4%
9294771,710.81,541.11,008.7246.21,924.21,381.61,674.2
Income Tax Paid Supplemental Data Ann.
-
-
---------
Interest Paid Supplemental Data Ann.
-
-
---------
Capex Ann.
-
-
---------
Issuance Of Capital Stock Ann.
-
-
---1,908.7--
Issuance Of Debt Ann.
-
-22.9%
3,229.51,471.23501,272.511,8911,100
Repayment Of Debt Ann.
-
-
-2,275-1,350-11,210.4-294-294-193
Repurchase Of Capital Stock Ann.
-
-
-1,227.4-229.7-304.8---
Free Cash Flow Ann.
5.1%
4.1%
2,489.82,7692,987.82,1442,017.52,034.61,667.21,618.31,418.3
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
-10.1%
2Y CAGR
-8.7%
3Y CAGR
5.1%
5Y CAGR
4.1%
7Y CAGR
6.3%
Cash from Operating Activity Annual is falling faster than historical averages.
×